Iwata H - Search Results

1

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, Moreno-Aspitia A, Doi T, Sagara Y, Redfern C, Krop IE, Lee C, Fujisaki Y, Sugihara M, Zhang L, Shahidi J, Takahashi S. Modi S, et al. Among authors: iwata h. J Clin Oncol. 2020 Jun 10;38(17):1887-1896. doi: 10.1200/JCO.19.02318. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058843 Free PMC article. Clinical Trial.

2

Dose-finding phase I and pharmacokinetic study of capecitabine (Xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer.

Saji S, Toi M, Morita S, Iwata H, Ito Y, Ohno S, Kobayashi T, Hozumi Y, Sakamoto J. Saji S, et al. Among authors: iwata h. Oncology. 2007;72(5-6):330-7. doi: 10.1159/000113062. Epub 2008 Jan 12. Oncology. 2007. PMID: 18187954 Clinical Trial.

3

A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.

Hayashi H, Kimura M, Yoshimoto N, Tsuzuki M, Tsunoda N, Fujita T, Yamashita T, Iwata H. Hayashi H, et al. Among authors: iwata h. Breast Cancer. 2009;16(2):136-40. doi: 10.1007/s12282-008-0060-1. Epub 2008 Jun 12. Breast Cancer. 2009. PMID: 18548321

4

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.

Tokudome N, Ito Y, Hatake K, Toi M, Sano M, Iwata H, Sato Y, Saeki T, Aogi K, Takashima S. Tokudome N, et al. Among authors: iwata h. Anticancer Drugs. 2008 Aug;19(7):753-9. doi: 10.1097/CAD.0b013e328302eb15. Anticancer Drugs. 2008. PMID: 18594220 Clinical Trial.

5

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.

Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Watanabe T, et al. Among authors: iwata h. J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204202 Clinical Trial.

6

Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer.

Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, Yatabe Y, Imai T, Ohashi Y. Sawaki M, et al. Among authors: iwata h. Breast. 2010 Oct;19(5):370-6. doi: 10.1016/j.breast.2010.03.021. Epub 2010 May 15. Breast. 2010. PMID: 20472435 Free article. Clinical Trial.

7

Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].

Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y. Sawaki M, et al. Among authors: iwata h. Jpn J Clin Oncol. 2011 May;41(5):709-12. doi: 10.1093/jjco/hyr011. Epub 2011 Feb 24. Jpn J Clin Oncol. 2011. PMID: 21355003 Clinical Trial.

8

High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.

Horio A, Fujita T, Hayashi H, Hattori M, Kondou N, Yamada M, Adachi E, Ushio A, Gondou N, Sueta A, Yatabe Y, Iwata H. Horio A, et al. Among authors: iwata h. Int J Clin Oncol. 2012 Apr;17(2):131-6. doi: 10.1007/s10147-011-0269-4. Epub 2011 Jun 18. Int J Clin Oncol. 2012. PMID: 21681642 Clinical Trial.

9

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M. Iwata H, et al. Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081. Jpn J Clin Oncol. 2011. PMID: 21719750 Clinical Trial.

10

Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.

Nakamura S, Ando M, Masuda N, Aogi K, Ino H, Iwata H, Tokuda Y, Yamamoto N, Kasai H, Takeuchi M, Tsuda H, Akiyama F, Kurosumi M, Fujiwara Y. Nakamura S, et al. Among authors: iwata h. Clin Breast Cancer. 2012 Feb;12(1):49-56. doi: 10.1016/j.clbc.2011.10.002. Epub 2011 Dec 6. Clin Breast Cancer. 2012. PMID: 22154118 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,964 results

Search Page